Skip to main content
Premium Trial:

Request an Annual Quote

As Expected, ABI Completes Equity Investment in VisiGen

NEW YORK, Dec. 9 (GenomeWeb News) - Applied Biosystems said yesterday that it has completed its equity investment in VisiGen Biotechnologies.


ABI announced its plans to invest in the company, which is developing next-generation sequencing technology, in October.


ABI has also entered into a scientific collaboration with VisiGen.


Financial terms of the transaction was not disclosed, although ABI's investment hinged on a follow-on investment from VisGen shareholder SeqWright.


SeqWright announced that it had made a second equity investment, of an undisclosed amount, in November.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.